BTIG analyst David Larsen has maintained their neutral stance on DH stock, giving a Hold rating on August 9.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
David Larsen has given his Hold rating due to a combination of factors that suggest both potential and challenges for Definitive Healthcare Corp. The company reported slightly better-than-expected results for the second quarter of 2025, with revenue and adjusted EBITDA surpassing consensus estimates. However, despite these improvements, the company is still facing significant challenges such as a decline in year-over-year revenue and ongoing attrition issues.
While there have been positive developments, such as a strong renewal rate and new data partnerships, the overall macroeconomic environment and elongated decision-making processes continue to pose headwinds. Additionally, the company’s enterprise customer base has decreased, and the revenue guidance for 2025 indicates a potential decline. Although the company has a strong cash flow and has made operational improvements, consistent revenue and EBITDA growth are necessary to drive the stock forward, leading to the Hold rating.
In another report released on August 9, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $4.00 price target.